|
| 34808460 | PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers. | Transl Oncol | 2022 |
| 35759659 | Activating STING1-dependent immune signaling in <i>TP53</i> mutant and wild-type acute myeloid leukemia. | Proc Natl Acad Sci U S A | 2022 |
| 35681619 | Pharmacologic Induction of BRCAness in <i>BRCA</i>-Proficient Cancers: Expanding PARP Inhibitor Use. | Cancers (Basel) | 2022 |
| 36009550 | LLL12B, a Novel Small-Molecule STAT3 Inhibitor, Induces Apoptosis and Suppresses Cell Migration and Tumor Growth in Triple-Negative Breast Cancer Cells. | Biomedicines | 2022 |
| 35091444 | Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia. | Clin Cancer Res | 2022 |
| 34504649 | Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal tandem duplication. | Oncotarget | 2021 |
| 33822747 | How Epigenetic Therapy Beats Adverse Genetics in Monosomy Karyotype AML. | Cancer Res | 2021 |
| 32238799 | Histone demethylase JMJD1A promotes expression of DNA repair factors and radio-resistance of prostate cancer cells. | Cell Death Dis | 2020 |
| 32824412 | Metastasis Suppressor NME1 Modulates Choice of Double-Strand Break Repair Pathways in Melanoma Cells by Enhancing Alternative NHEJ while Inhibiting NHEJ and HR. | Int J Mol Sci | 2020 |
| 32651270 | Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency. | Proc Natl Acad Sci U S A | 2020 |
| 30691684 | Exploiting epigenetically mediated changes: Acute myeloid leukemia, leukemia stem cells and the bone marrow microenvironment. | Adv Cancer Res | 2019 |
| 31591209 | DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation. | Proc Natl Acad Sci U S A | 2019 |
| 30953707 | Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD. | Cancer Lett | 2019 |
| 29615458 | An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations. | Clin Cancer Res | 2018 |
| 30389813 | Retraction: Aromatase Inhibitor-mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer. | Mol Cancer Ther | 2018 |
| 28486105 | CHD4 Has Oncogenic Functions in Initiating and Maintaining Epigenetic Suppression of Multiple Tumor Suppressor Genes. | Cancer Cell | 2017 |
| 26797621 | Hydroxylated Dimeric Naphthoquinones Increase the Generation of Reactive Oxygen Species, Induce Apoptosis of Acute Myeloid Leukemia Cells and Are Not Substrates of the Multidrug Resistance Proteins ABCB1 and ABCG2. | Pharmaceuticals (Basel) | 2016 |
| 27728808 | Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer. | Cancer Cell | 2016 |
| 27688775 | High-Fidelity Reprogrammed Human IPSCs Have a High Efficacy of DNA Repair and Resemble hESCs in Their MYC Transcriptional Signature. | Stem Cells Int | 2016 |
| 27374090 | Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress. | Oncotarget | 2016 |
| 27064363 | Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin. | Leuk Res | 2016 |
| 25766563 | A "RANning" leap with "XPOrt" into TKI resistance. | Blood | 2015 |
| 25828893 | c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias. | Mol Cancer Res | 2015 |
| 25976679 | Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer. | Mol Cancer Ther | 2015 |
| 23958061 | Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome. | Leuk Res | 2014 |
| 25441683 | High frequency of rare structural chromosome abnormalities at relapse of cytogenetically normal acute myeloid leukemia with FLT3 internal tandem duplication. | Cancer Genet | 2014 |
| 24163065 | Vascular progenitors from cord blood-derived induced pluripotent stem cells possess augmented capacity for regenerating ischemic retinal vasculature. | Circulation | 2014 |
| 22641215 | Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias. | Oncogene | 2013 |
| 23836560 | Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. | Blood | 2013 |
| 22995214 | DNA double-strand break response in stem cells: mechanisms to maintain genomic integrity. | Biochim Biophys Acta | 2013 |
| 22112941 | Targeting abnormal DNA repair in therapy-resistant breast cancers. | Mol Cancer Res | 2012 |
| 23088869 | HDAC inhibitors: roles of DNA damage and repair. | Adv Cancer Res | 2012 |
| 22439938 | Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. | Cancer Cell | 2012 |
| 22427031 | Genomic instability in chronic myeloid leukemia: targets for therapy? | Curr Hematol Malig Rep | 2012 |
| 21228325 | Defective nonhomologous end joining blocks B-cell development in FLT3/ITD mice. | Blood | 2011 |
| 21543117 | KLFs and ATRA-induced differentiation: new pathways for exploitation. | Leuk Res | 2011 |
| 21718709 | Human induced pluripotent cells resemble embryonic stem cells demonstrating enhanced levels of DNA repair and efficacy of nonhomologous end-joining. | Mutat Res | 2011 |
| 20219246 | Regulation of differentiation by a PHD domain in the NUP98-PHF23 fusion protein. | Leuk Res | 2010 |
| 20697770 | Targeting abnormal DNA double strand break repair in cancer. | Cell Mol Life Sci | 2010 |
| 20841480 | Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells. | Cancer Res | 2010 |
| 20807885 | Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy. | Blood | 2010 |
| 18192505 | Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. | Blood | 2008 |
| 18467025 | Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. | Cancer Lett | 2008 |
| 18524993 | Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks. | Blood | 2008 |
| 18524763 | BCL6-mediated attenuation of DNA damage sensing triggers growth arrest and senescence through a p53-dependent pathway in a cell context-dependent manner. | J Biol Chem | 2008 |
| 17875717 | Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? | Cancer Res | 2007 |
| 16545529 | Molecular cloning of Chinese hamster 1q31 chromosomal fragile site DNA that is important to mdr1 gene amplification reveals a novel gene whose expression is associated with spermatocyte and adipocyte differentiation. | Gene | 2006 |
| 16877702 | Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis? | Mol Cancer Res | 2006 |
| 14737073 | Differentially expressed genes in adult familial myelodysplastic syndromes. | Leukemia | 2004 |
| 12691817 | DNA double strand breaks (DSB) and non-homologous end joining (NHEJ) pathways in human leukemia. | Cancer Lett | 2003 |